No Means No: Genzyme Responds To Sanofi's Hostile Bid
Sanofi CEO Viehbacher indicated a price of $69- to $80-per-share would be acceptable, Genzyme reveals in an SEC filing.
Sanofi CEO Viehbacher indicated a price of $69- to $80-per-share would be acceptable, Genzyme reveals in an SEC filing.